Silence Therapeutics PLC Sponsored ADR (SLN) shares soared 5.7% in the last trading session to close at $22.36. The move was backed by solid volume with far more shares changing hands than in a normal ...
Silence Therapeutics PLC ADR Annual stock financials by MarketWatch. View the latest SLN financial statements, income statements and financial ratios.
Goldman Sachs initiated Silence Therapeutics (NASDAQ:SLN) with a Sell rating and a $6 price target on Tuesday, arguing that with only about $173M of cash and equivalents at the end of Q3 2024, the U.K ...
A newly released economic impact study by the Docking Institute of Public Affairs at Fort Hays State University confirms the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback